We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · August 30, 2021

Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder

Clinical Genitourinary Cancer

 

Additional Info

Clinical Genitourinary Cancer
A Single-Arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder
Clin Genitourin Cancer 2021 Feb 18;[EPub Ahead of Print], A Challapalli, S Masson, P White, N Dailami, S Pearson, E Rowe, A Koupparis, J Oxley, A Abdelaziz, J Ash-Miles, A Bravo, E Foulstone, C Perks, J Holly, R Persad, A Bahl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading